期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胃癌的分子靶向治疗 被引量：2

胃癌的分子靶向治疗
原文传递
导出
摘要 晚期胃癌患者的治疗主要为全身化疗,但胃癌的化疗总体来讲尚没有一致公认的标准方案,迫切需要新疗法出现。分子靶向治疗以某些标志性分子为靶点,有效干预受该分子调控并与肿瘤发展密切相关的信号通路,是目前肿瘤治疗领域发展的新方向。目前应用分子靶向治疗胃癌主要有以下几种机制。
作者 张路
机构地区 北京协和医学院北京协和医院物理康复科
出处 《中国肿瘤临床与康复》 2012年第2期190-192,共3页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 胃肿瘤 靶向治疗 Stomach neoplasms Targeted therapy
分类号 R735.2 [医药卫生—肿瘤] R730.54 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1James P. Thomas,Kendra D. Tutsch,James F. Cleary,Howard H. Bailey,Rhoda Arzoomanian,Dona Alberti,Kris Simon,Chris Feierabend,Kimberly Binger,Rebecca Marnocha,Amy Dresen,George Wilding.Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol[J].Cancer Chemotherapy and Pharmacology.2002(6)
  • 2Doi T,Koizumi W.Efficacy,tolerability and pharmacokinetics ofgefi-tinib (ZD1839)in pretreated patients with metastatic gastriccancer[].Proceedings of the American Society of Clinical Oncology.2003
  • 3Tokuyama J,Kubota T,Saikawa Y,et al.Tyrosine kinase inhibi-tor SU6668 inhibits peritoneal dissemination of gastric cancer viasupresion of tumor angiogenesis[].Anticancer Research.2005
  • 4Shah MA,Kortmansky J,Gonen M,et al.PhaseⅠstudy of week-ly irinotecan (CPT) cisplatin (CIS)and flavopiridol (F)[].Proceedings of the American Society of Clinical Oncology.2004
  • 5RI Nicholson,JMW Gee,ME Harper.EGFR and cancer prognosis[].European Journal of Cancer.2001
  • 6Doi T,Ohtsu A,Saijo N,Takiuchi H,Ohhashi Y,Weber D,Tillner J,Sakata T,Sun H,Rojo F.A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody "EMD72000 (Matuzumab)" administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies[].Journal of Clinical Oncology.2005
  • 7Trarbach T,SchleucherN,W eber D,et al.Phase I study of thehuman ized anti-ep idermal growth factor receptor(EGFR)anti-body EMD 72000(matuzumab)in comb ination w ith cisplatin,5-fluorouracil and leucovorin(PFL)in patients(pts)w ith ad-vanced esophago-gastric(EG)adenocarcinoma[].Proc Am SocC lin Oncol.2005
  • 8Doi T,Koizumi W,Siena S,et al.Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer[].Proceedings of the American Society of Clinical Oncology.2003
  • 9T Dragovich,S McCoy,CM Fenoglio-Preiser.Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127[].Journal of Clinical Oncology.2006
  • 10Gravalos C,Jimeno A.HER2in gastric cancer:a new prognostic factor and a novel therapeutic tar-get[].Annals of Oncology.2008

同被引文献21

  • 1Siegel R,Naishadham D,Jemal A. Cancer statistics,2012. CA Cancer J Clin,2012,62( 1 ) : 10-29.
  • 2Ding GB,Liu HY,Lv YY,et al. Enhanced in vitro antitumor efficacy and strong anti-cell-migration activity of a hydroxycamptothecinencapsulated magnetic nanovehicle. Chemistry,2012,18 (44): 14037-14046.
  • 3Yu P,Xia L,Zhao J,et al. Synthesis and preliminary anticancer evaluation of lO-hydroxycamptothecin analogs. Biol Pharm Bull, 2012, 35(8 ) : 1295-1299.
  • 4Lu H, Sun HZ, Li H, et al. The clinicopathological significance of Bmi-1 expression in pathogenesis and progression of gastric carcinomas. Asian Pac J Cancer Prey, 2012,13 (7) : 3437-3441.
  • 5Li W,Li Y,Tan Y,et al. Bmi-1 is critical for the proliferation and invasiveness of gastric carcinoma cells. J Gastroenterol Hepatol, 2010,25(3):568-575.
  • 6Siegel R,Naishadham D,Jemal A. Cancer statis-tics, 2012[J].CA Cancer J Clin, 2012, 62(1): 10 —29.
  • 7Shah MA, Power DG, Kindler HL et al. A multi-center, phase II study of bortezomib (PS-341) inpatients with unresectable or metastatic gastric andgastroesophageal junction adenocarcinoma [ J ]. In-vest New Drugs, 2011, 29(6) : 1475 —1481.
  • 8Weber DM, Graef T, Hussein M,et al. Phase Itrial of vorinostat combined with bortezomib for thetreatment of relapsing and/or refractory multiplemyeloma [J]. Clin Lymphoma Myeloma Leuk,2012, 12(5):319—324.
  • 9Li W,Li Y, Tan Y,et al. Bmi-1 is critical for theproliferation and invasiveness of gastric carcinomacells[J]. J Gastroenterol Hepatol, 2010,25(3):568-575.
  • 10陈万青,张思维,郑荣寿,雷正龙,李光琳,邹小农,赵平.中国肿瘤登记地区2007年肿瘤发病和死亡分析[J].中国肿瘤,2011,20(3):162-169. 被引量：331

引证文献2

二级引证文献2

中国肿瘤临床与康复
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部